Burow Kristina 4

What Happened
Kristina Burow, reported as a 10% owner of Neumora Therapeutics, was granted 80,000 derivative shares (transaction code A — grant/award) on 2026-05-27. The award shows an acquisition price of $0.00 (no cash paid). This was an equity-linked grant — not an open-market purchase or sale — and does not represent an immediate sale of shares.

Key Details

• Transaction date: 2026-05-27; Form 4 filed: 2026-05-29 (timely filing).
• Amount: 80,000 derivative shares granted at $0.00.
• Transaction code: A = Grant / award (derivative securities).
• Vesting (footnote F1): 100% of the shares vest on the earlier of (i) the one-year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No exercise, sale, tax-withholding, or 10b5-1 plan reported in this filing.

Context
This grant likely represents stock options or RSUs that will become actual shares only after vesting; there was no immediate cash flow or sale associated with the grant. As a 10% owner, Burow is a significant holder — such insider awards are routine ways companies align holders with long-term performance but do not on their own indicate a buy/sell signal to the market.